Neurocrine and Wyeth extend EAAT-3 agreement
By Business Review Editor
Pharma Deals Review: Vol 2002 Issue 24 (Table of Contents)
Published: 2 May-2002
DOI: 10.3833/pdr.v2002.i24.1058 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Neurocrine and Wyeth extended their research agreement for a further year to discover, develop and commercialize compounds that modulate excitatory amino acid transporters for treating neurodegenerative and psychiatric diseases...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS